The estimated Net Worth of Jill Buck is at least $388 ezer dollars as of 8 January 2021. Ms. Buck owns over 27,894 units of Alaunos Therapeutics Inc stock worth over $173,579 and over the last 5 years she sold ZIOP stock worth over $214,079. In addition, she makes $0 as Executive Vice President, General Manager és Gene Therapy at Alaunos Therapeutics Inc.
Jill has made over 2 trades of the Alaunos Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 27,894 units of ZIOP stock worth $87,029 on 8 January 2021.
The largest trade she's ever made was selling 27,923 units of Alaunos Therapeutics Inc stock on 2 January 2020 worth over $127,050. On average, Jill trades about 13,954 units every 93 days since 2020. As of 8 January 2021 she still owns at least 199,516 units of Alaunos Therapeutics Inc stock.
You can see the complete history of Ms. Buck stock trades at the bottom of the page.
Jill Yannetti Buck serves as Executive Vice President, General Manager, Gene Therapy of the Company. Ms. Buck has served as our Executive Vice President, General Manager Gene Therapy since January 2019 and served as our Senior Vice President of Clinical Operations from January 2017 to January 2019, and as our Vice President of Clinical Operations from September 2015 to January 2017. Previously, Ms. Buck served as Group Vice President of Global Clinical Operations at Synageva Biopharm Corp from January 2014 to September of 2015, and Vice President of Global Clinical Operations from June 2013 to January 2014 where she oversaw the teams responsible for the clinical trials resulting in US, EU and Japanese approvals of sebelipase alfa for LAL Deficiency. Prior to Synageva, Ms. Buck held roles of increasing responsibility in Clinical Operations at the Company, Averion International, Control Delivery Systems and The TIMI Study Group at Brigham and Women’s Hospital. Ms. Buck holds a BA degree in English and Communications from Boston College.
Jill Buck is 46, she's been the Executive Vice President, General Manager és Gene Therapy of Alaunos Therapeutics Inc since 2019. There are 16 older and 1 younger executives at Alaunos Therapeutics Inc. The oldest executive at Alaunos Therapeutics Inc is J. Kevin Buchi, 65, who is the Director.
Jill's mailing address filed with the SEC is ONE FIRST AVENUE, PARRIS BUILDING 34, NAVY YARD PLAZA, BOSTON, MA, 02129.
Over the last 18 years, insiders at Alaunos Therapeutics Inc have traded over $2,792,771 worth of Alaunos Therapeutics Inc stock and bought 7,941,160 units worth $39,823,909 . The most active insiders traders include Randal J Kirk, Randal Jintrexon Corp Kirk és Lindsay A Md Rosenwald. On average, Alaunos Therapeutics Inc executives and independent directors trade stock every 72 days with the average trade being worth of $152,086. The most recent stock trade was executed by Groot Eleanor De on 22 December 2021, trading 20,132 units of ZIOP stock currently worth $25,568.
Ziopharm Oncology is an immuno-oncology company focused on developing end-to-endcost-effective solutions using its non-viralSleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12 (IL-12). The Sleeping Beauty platform genetically modifies T cells with DNA plasmids to express T-cell receptors (TCRs) to target specific antigens in solid tumors and chimeric antigen receptors (CARs) to target CD19 in blood cancers with the Company's 3rd generation T-cell manufacturing process, rapid personalized manufacture (RPM). The Sleeping Beauty platform is being advanced in collaboration with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Eden BioCell. The Company also is developing its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex, as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer, including in collaboration with Regeneron Pharmaceuticals.
Alaunos Therapeutics Inc executives and other stock owners filed with the SEC include: